semaglutide constipation class action in kentucky Ozempic Lawyer GLP-1 Overdose & Pharmaceutical Negligence

And the supply-and-demand mismatch produced a gray-market secondary economy in research peptides that, by any rational read, will be remembered as one of the strangest health-consumer stories of the decade

Adding MOTS-C to a Retatrutide protocol has fixed that pattern in patients Ive worked with at Formation

The total number of pending actions is now 2,947

People with contraindications, such as a history of pancreatitis or thyroid cancer, should consult their provider about potential risks

TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief Eli Lilly and Company has announced positive topline results from the phase 3 TRIUMPH-4 clinical trial assessing the safety and efficacy of the 2 largest investigational doses of retatrutide in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity.1 According to a December 11, 2025, release from the Company, both the 9 mg and 12 mg doses of the first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist met all primary and key secondary endpoints, delivering significant weight loss and improvements in pain and physical function at 68 weeks using both the efficacy and treatment-regimen estimands.1 "People with obesity and knee osteoarthritis often live with pain and restricted mobility, and may eventually require total joint replacement," said Kenneth Custer , PhD, executive vice president and president, Lilly Cardiometabolic Health.1 "We are encouraged by the results of TRIUMPH-4, which highlight the powerful effect of retatrutide, a first-in-class triple agonist, on body weight, pain and physical function